Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Cytokine1 who wrote (6998)	8/22/1999 2:06:00 PM
From: WTDEC	Respond to of 9719

CLTR News is out. Score another for V1...>) Coulter Pharmaceutical and SmithKline Beecham Announce Priority Review Status for Bexxar Business Wire - July 22, 1999 06:19 SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--July 22, 1999-- Coulter Pharmaceutical, Inc. (Nasdaq:CLTR) and SmithKline Beecham (NYSE:SBH) today announced that Bexxar(TM) (tositumomab, iodine I 131 tositumomab) has been assigned priority review status by the U.S. Food and Drug Administration. Priority review status indicates that the license application for Bexxar will be reviewed and action taken by the agency within six months from the June 30, 1999 date of submission. If approved, Bexxar could be the first radioimmunotherapy to become commercially available. "We are delighted to receive priority review status for Bexxar," said Michael F. Bigham, president and chief executive officer of Coulter. "It underscores the FDA's commitment to expeditiously review our license application. Snip> Best regards, Walter

To: Cytokine1 who wrote (6998)	8/22/1999 5:44:00 PM
From: WTDEC	Respond to of 9719

Sorry about the prior post...I messed up and thought it was a new release dated August 22, today, rather than the actual date of July 22. :-(

To: Cytokine1 who wrote (6998)	8/23/1999 8:12:00 PM
From: Cytokine1	Read Replies (2) \| Respond to of 9719

VD's MODEL PORTFOLIO 8/23/99 Change $13281 UP 3.38% Started 4/9/97, $100K . INDEX ^IXB UP 4.30% YTD EQUITY CHANGE 34.4% # CURRENT DAILY CURRENT COST TOTAL %GAIN/ % OF SYMBOL SHRS PRICE CHANGE %CHG VALUE SHR COST LOSS TOTAL ======= ======= ======= ======= ======= ======= ======= ======= ======= ======= BTRN 6000 5.50 -0.25 -4.35% 33000 2.25 13500 144.4% 8.1% CLTR 2500 31.00 2.13 7.36% 77500 17.31 43281 79.1% 19.1% MOGN 3000 12.00 0.25 2.13% 36000 8.667 26000 38.5% 8.9% CELG 2500 16.50 0.50 3.13% 41250 15.71 39275 5.0% 10.2% CGPI 2000 10.88 0.50 4.82% 21750 9.00 18000 20.8% 5.4% INHL 1000 33.38 3.75 12.66% 33375 24.50 24500 36.2% 8.2% SEPR 500 81.50 4.00 5.16% 40750 78.20 39100 4.2% 10.0% INCY 2000 25.19 0.00 0.00% 50375 28.95 57909 -13.0% 12.4% ABSC 3000 8.84 0.34 4.04% 26531 8.761 26283 0.9% 6.5% GZTC 2000 6.38 0.13 2.00% 12750 7.737 15475 -17.6% 3.1% GLIA 1500 22.00 -0.38 -1.68% 33000 22.979 34469 -4.3% 8.1% STOCK ______ ______ ______ ______ 406281 337791 20.3% 100.0% SHORT SALE CREDIT ______ ______ 0 MARGIN MTCE. EQUITY 61.1% MIN 30% (157844) BUYING POWER $ ______ 90594 EQUITY (NAV) ______ ______ ______ 248437 100000 148.4% ^IXB INDEX 638.31 26.29 4.30% 302.42 111.1% NOTES: OPEN orders subject to available buying power--- INCY limit buy 1000 @ $20.00 08/14/1999 -15625 BUY 1000 CELG @ $15.625 08/05/1999 57250 SOLD 1000 MLNM @ $57.25 07/29/1999 -8812.5 BUY 1000 ABSC @ 8.8125 07/23/1999 -24500 BUY 1000 INHL @ $24.50 07/23/1999 9375 SELL 2000 GSII @ $4.6875 07/16/1999 7437.5 INIS sold 1000 @ $7.4375 07/12/1999 -10375 CLTR bought 500 @ $20.75 07/12/1999 -8437.5 CELG bought 500 @ $16.875 07/12/1999 -11468.75 GLIA bought 500 @ $22.9375